One Goal. One Passion. Every Patient. Every Time.
Cardiology

Interventional Cardiology

RESEARCH

INVESTIGATIVE PHARMACOLOGIC THERAPY FOR CONGESTIVE HEART FAILURE (CHF)

Although new medications for congestive heart failure (CHF) have improved morbidity and mortality (e.g., ACE inhibitors, angiotensin receptor blockers, beta blockers), readmission rates and mortality remain high. Novel pharmacologic treatment strategies are being studied:

Protocol: "Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of Single Oral Tolvaptan Tablets on Hemodynamic Parameters in Subjects with Heart Failure"

ECLIPSE TRIAL

Principal Investigator: Marc Klapholz, MD

Protocol: "A phase II, Randomized, Placebo-Controlled, Single-Blind, Multi-Center, Dose-Escalation, Study To Evaluate Tolerability, Safety, Pharmacokinetics, and Pharmacodynamics of A Single Intravenous Administration of INO-1001 In Subjects with STEMI Undergoing Primary Percutaneous Coronary Intervention"

IRB #: 0120050061

TIMI 37A TRIAL

Principal Investigator: Marc Klapholz, MD

Protocol: "Safety and Tolerability of PST 2744 in Adults with Chronic Heart Failure, A Phase I-II Study" IRB #: 0120040346

PST 2744 TRIAL

Principal Investigator: Marc Klapholz, MD

Protocol: "Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Long Term Efficacy and Safety of Oral Tolvaptan Tablets in Subjects Hospitalized with Worsening Congestive Heart Failure"

EVEREST TRIAL

Principal Investigator: Marc Klapholz, MD

Protocol: "Multicenter trial of the Orqis Medical CRS for the Enhanced Treatment of CHF Unresponsive to Medical Therapy"

MOMENTUM TRIAL

Principal Investigator: Marc Klapholz, MD

Protocol: "A randomized Dose-Ranging Study of Hexadecasaccharide including Active Control, in Patients with Unstable Angina or Non-ST-segment Elevation Myocardial

Infarction Scheduled to Undergo Percutaneous Coronary Intervention"

SHINE STUDY

Principal Investigator: Kamran Hamirani, MD

Protocol: "Warfarin Versus Aspirin in Reduced Cardiac Ejection Fraction"

WARCEF STUDY

Principal Investigator: Christine Gerula, MD

INVESTIGATOR INITIATED RESEARCH

Division of Cardiology(Marc Klapholz, MD)

Acute Treatment of Decompensated Normal EF Heart Failure with Natrecor

STAT MI: Wireless Technology to Shorten Door to Balloon Time in Primary Angioplasty

Aldosterone Modification of Osteopontin Levels in Patients with Low EF Heart Failure and End Stage Renal Disease

Carvedilol Use in the Management of Cocaine Induced Myocardial Ischemia

Use of Perfusion Echocardiography in ICU Patients with Non-ST Elevation MI

All projects are available for residents and/or student participation.

CARDIAC DISORDERS

AORTIC ANEURYSM

The aorta is the largest blood vessel in the body. All the oxygenated blood for the body is pumped out of the heart through this artery. It is then distributed to the body through a series of progressively smaller vessels. An aneurysm is a condition in which an area of an artery's wall weakens and balloons out past its normal size. If the aneurysm occurs near the heart, in the aorta, it is called a thoracic (chest) aortic aneurysm; however, aneurysms can also develop in other parts of the body, such as the abdomen and the brain. Thoracic aortic aneurysms are relatively uncommon; most aneurysms-about 75 percent-occur in the abdomen. However, aortic aneurysms are prone to rupture once they reach a certain size. Fifty percent of patients who experience a rupture of a thoracic aortic aneurysm will die before reaching the hospital. Furthermore, surgical repair of a ruptured thoracic aneurysm carries a 25-50% mortality as opposed to a 5-8% mortality when such aneurysms are treated electively.